Vanguard Group’s Opiant Pharmaceuticals, Inc. Common Stock OPNT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-190,773
| Closed | -$3.87M | – | 4615 |
|
|
2022
Q4 | $3.87M | Buy |
190,773
+3,615
| +2% | +$55.4K | ﹤0.01% | 3425 |
|
|
2022
Q3 | $2.01M | Hold |
187,158
| – | – | ﹤0.01% | 3740 |
|
|
2022
Q2 | $2.24M | Hold |
187,158
| – | – | ﹤0.01% | 3759 |
|
|
2022
Q1 | $4.01M | Buy |
187,158
+8,699
| +5% | +$230K | ﹤0.01% | 3631 |
|
|
2021
Q4 | $6M | Buy |
178,459
+40,689
| +30% | +$1.13M | ﹤0.01% | 3508 |
|
|
2021
Q3 | $3.55M | Buy |
137,770
+805
| +0.6% | +$14.4K | ﹤0.01% | 3841 |
|
|
2021
Q2 | $1.83M | Buy |
136,965
+23,935
| +21% | +$296K | ﹤0.01% | 3989 |
|
|
2021
Q1 | $1.2M | Buy |
113,030
+14,101
| +14% | +$161K | ﹤0.01% | 3976 |
|
|
2020
Q4 | $794K | Sell |
98,929
-3,422
| -3% | -$26.9K | ﹤0.01% | 3879 |
|
|
2020
Q3 | $766K | Sell |
102,351
-3,971
| -4% | -$35.3K | ﹤0.01% | 3719 |
|
|
2020
Q2 | $960K | Hold |
106,322
| – | – | ﹤0.01% | 3624 |
|
|
2020
Q1 | $1.02M | Hold |
106,322
| – | – | ﹤0.01% | 3488 |
|
|
2019
Q4 | $1.53M | Hold |
106,322
| – | – | ﹤0.01% | 3522 |
|
|
2019
Q3 | $1.65M | Sell |
106,322
-18,251
| -15% | -$254K | ﹤0.01% | 3509 |
|
|
2019
Q2 | $1.65M | Hold |
124,573
| – | – | ﹤0.01% | 3525 |
|
|
2019
Q1 | $1.64M | Buy |
124,573
+1,573
| +1% | +$22.9K | ﹤0.01% | 3510 |
|
|
2018
Q4 | $1.78M | Buy |
123,000
+17,568
| +17% | +$287K | ﹤0.01% | 3411 |
|
|
2018
Q3 | $1.88M | Buy |
105,432
+21,151
| +25% | +$366K | ﹤0.01% | 3559 |
|
|
2018
Q2 | $1.2M | Buy |
84,281
+3,550
| +4% | +$62.4K | ﹤0.01% | 3639 |
|
|
2018
Q1 | $1.55M | Buy |
80,731
+71,170
| +744% | +$1.54M | ﹤0.01% | 3541 |
|
|
2017
Q4 | $220K | Buy |
+9,561
| New | +$306K | ﹤0.01% | 3917 |
|
Vanguard Group's OPNT Position: Q1 2023 in Review
Vanguard Group sold out of Opiant Pharmaceuticals, Inc. Common Stock (OPNT) in Q1 2023, closing a stake of 190,773 shares — an estimated $3.87M sold.
Vanguard Group first reported a position in OPNT in Q4 2017 and held it in 21 quarters. The position peaked at $6M in Q4 2021. 0 funds tracked by Wall St. Rank hold OPNT as of Q1 2023.
- Vanguard Group reported no remaining Opiant Pharmaceuticals, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
- Vanguard Group sold 190,773 Opiant Pharmaceuticals, Inc. Common Stock shares in Q1 2023, an estimated $3.87M.
- Vanguard Group first reported a position in Opiant Pharmaceuticals, Inc. Common Stock in Q4 2017 and held it in 21 quarters.
- Vanguard Group's Opiant Pharmaceuticals, Inc. Common Stock position peaked at $6M in Q4 2021.
- 0 funds tracked by Wall St. Rank held Opiant Pharmaceuticals, Inc. Common Stock as of Q1 2023.
Based on Vanguard Group's 13F filing for Q1 2023, filed 15 May 2023.